Biocept announces enrollment of the first patient in the FORESEE clinical trial with the Company’s proprietary cerebrospinal fluid assay CNSide. The FORESEE trial is a multicenter, prospective clinical trial expected to enroll 40 patients with breast or non-small cell lung cancer who have suspicious or confirmed leptomeningeal metastases. The goal of the FORESEE trial is to evaluate the performance of CNSide in monitoring the LM’s response to treatment and to assess the impact of CNSide on treatment decisions made by physicians. This first patient was seen at the UT Southwestern Medical Center, one of the largest and most respected hospitals in the nation. "The enrollment of the first patient in the FORESEE clinical study is a major milestone for the management of patients with leptomeningeal disease," said Michael Youssef, MD, Assistant Professor in the Department of Neurology and the Department of Hematology and Oncology at UT Southwestern Medical Center. "We are excited to be at the forefront of this innovation, which will greatly benefit patients."
Published first on TheFly
